Innovent Biologics reported that efdamrofusp alfa (IBI-302) met the primary endpoint in its Phase 3 Star trial in neovascular age-related macular degeneration (nAMD). The Suzhou-based company said it will submit an NDA to China’s National Medical Products Administration, moving the candidate toward potential approval in an established ophthalmology market. The Phase 3 outcome, according to Innovent, supports the next regulatory milestone, while clinicians and payers will evaluate the full package of efficacy and safety across dosing regimens. Companies competing in nAMD continue to differentiate around durability and administration convenience. Innovent’s announcement also reinforces China’s continued buildout of late-stage biologics for ophthalmic indications.